Chloroquine Tablets

Formulated to target malaria parasites to support resolution of infection.

Strengths: 250 · 500mg

Medicine details

Alternative names

Avloclor; Nivaquine

Therapeutic class

Antimalarial

Pharmacological class

4-Aminoquinoline

Known off-label uses

lupus erythematosus

Contraindications

hypersensitivity to chloroquine; retinal changes; epilepsy

Precautions and warnings

regular eye examinations required during long-term use; may impair vision

Minor side effects

nausea; headache; dizziness

Moderate side effects

skin rash; visual disturbances

Dosage forms

Tablet

Administration route

Oral use

Patient summary

Formulated to target malaria parasites to support resolution of infection.

Prescription status

POM

Manufacturer

Sanofi

Onset Time

1–2 hours

Duration

Indeterminate

Storage instructions

Store in a cool, dry place.

Drug interactions

Antacids; Ciclosporin

Age restrictions

Dosing should be adjusted according to weight.

Pregnancy and breastfeeding

Pregnancy: consult your doctor. Breastfeeding: use only if essential.

Serious side effects

retinopathy — requires immediate medical attention; cardiomyopathy — requires immediate medical attention

Mechanism of action

Interferes with the parasite's ability to detoxify heme within its food vacuole, resulting in an accumulation of toxic heme and the subsequent death of the parasite in the host blood cells.

Chloroquine Tablets

Formulated to target malaria parasites to support resolution of infection.

Editorial Notes

  • Active ingredient(s): Chloroquine
  • Listed indication(s): Malaria, Rheumatoid Arthritis

Usually available as

  • 180 tablets - 250 mg1128-250-mg-13357
  • 180 tablets - 500 mg1128-500-mg-13363